Oxaliplatin: A new drug for the treatment of metastatic carcinoma of the colon or rectum

Reviews in Gastroenterological Disorders

Volumn 3, Issue 1, 2003, Pages 31-38

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Eloxatin; Metastatic carcinoma of the colon or rectum; Oxaliplatin

Indexed keywords

ADRENALIN; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; DNA; ERYTHROMYCIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANISETRON; IRINOTECAN; MAGNESIUM; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; RALTITREXED; SALICYLIC ACID; SEROTONIN 3 ANTAGONIST; UNINDEXED DRUG; VALPROIC ACID;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; BACKACHE; BLOOD TOXICITY; CANCER RECURRENCE; CELL CYCLE; CLINICAL TRIAL; COLON CARCINOMA; DISEASE COURSE; DNA REPLICATION; DNA TRANSCRIPTION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SPECIFICITY; DRUG URINE LEVEL; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IN VITRO STUDY; METASTASIS; NEUROPATHY; NONHUMAN; RECTUM CARCINOMA; RESPIRATORY TRACT DISEASE; REVIEW; STOMATITIS;

ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PRODUCT SURVEILLANCE, POSTMARKETING; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0037412471     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Eloxatin [package insert]. New York, NY: Sanofi-Synthelabo Inc; August 9, 2002.
2. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053-1071.
3. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25(2 suppl 5):4-12.
4. Becouarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit Rev Oncol Hematol. 2001;40:265-272.
5. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855-1865.
6. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25(2 suppl 5):13-22.
7. Gamelin E, Le Bouil AL, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res. 1997;3:891-899.
8. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45:157-164.
9. Iacono LC, Spunt SL, Pratt CB, et al. Pharmacokinetics of oxaliplatin in children with solid tumors. Abstract presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 2170.
10. Temple R. Approval letter for NDA 21-492. Rockville, Md: Office of Drug Evaluation I, Center for Drug Evaluation and Research, Food and Drug Administration; August 9, 2002.
11. New drug regimen shows clear benefit for treating advanced colorectal cancer [press release]. Bethesda, Md: National Cancer Institute, National Institutes of Health, News from the NCI, May 18, 2002. Available at: http://newscenter.cancer.gov/pressreleases/ASCON9741.html. Accessed August 2, 2002.
12. Digest page: oxaliplatin. National Cancer Institute, cancer.gov Web site. May 18, 2002. Available at: http://www.nci.nih.gov/ClinicalTrials/developments/oxaliplatin. Accessed August 2, 2002.
13. Goldberg RM, Morton RF, Sargent DJ, et al. N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC): initial toxicity and response data from a GI intergroup study. Abstract presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 511.
14. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluororacil, leucovorin, oxaliplatin, and surgery. Ann Oncol. 1999;10:663-669.
15. Tournigand C, Maindrault-Goebel F, Louvet C, et al. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer. 1998;34:1297-1298.
16. Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule [letter]. J Clin Oncol. 2002;20:1146-1147.
17. Dold F, Hoey D, Carberry M, et al. Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Abstract presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 1478.
18. Gamelin E, Gamelin L, Delva R, et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: a retrospective study. Abstract presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18-21, 2002; Orlando, Fla. Abstract 624.
19. Metzger G, Massari C, Etienne MC, et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin Pharmacol Ther. 1994;56:190-201.
20. Boisdron-Celle M, Craipeau MC, Brienza S, et al. Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemother Pharmacol. 2002;49:235-243.
21. Levi F, Metzger G, Massari C, Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet. 2000;38:1-21.